How federal funding cuts could threaten America’s lead in cancer research

Cancer research in the U.S. doesn’t rely on a single institution or funding stream—it’s a complex ecosystem made up of interdependent parts: academia, pharmaceutical companies, biotechnology startups, federal agencies, and private foundations. As a cancer biologist who has worked in each of these sectors over the past three decades, I’ve seen firsthand how each piece supports the others.

When one falters, the whole system becomes vulnerable.

The United States has long led the world in cancer research.